NCT05215574 - Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors | Biotech Hunter

Enrollment

130

Participants

Timeline

Start Date

March 31, 2022

Primary Completion Date

July 31, 2025

Study Completion Date

March 31, 2026

Conditions

Pancreatic CancerBreast CancerGastric CancerNon-small Cell Lung CancerCervical CancerEndocervical CancerSquamous Cell Carcinoma of Head and NeckBladder Urothelial CancerColorectal CarcinomaEsophageal CancerOvarian CancerRenal Cell CarcinomaProstate CancerMelanomaMesotheliomaCholangiocarcinoma

Interventions

DRUG

NGM831

Drug: NGM831 NGM831 is given intravenously (IV) every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated.

DRUG

NGM831 plus pembrolizumab (KEYTRUDA®)

"Drug: NGM831 NGM831 is given intravenously (IV) every 3 weeks in a 21day cycle. Multiple dose levels will be evaluated.~Drug: pembrolizumab (KEYTRUDA®) pembrolizumab (KEYTRUDA®) will be administered intravenously (IV) every 3 weeks in a 21day cycle."

DRUG

NGM831 and NGM438 plus pembrolizumab (KEYTRUDA®)

"Drug: NGM831 NGM831 is given intravenously (IV) every 3 weeks in a 21-day cycle. Multiple dose levels will be evaluated.~Drug: NGM438 NGM438 is given intravenously (IV) every 3 weeks in a 21-day cycle. Multiple dose levels will be evaluated.~Drug: pembrolizumab (KEYTRUDA®) pembrolizumab (KEYTRUDA®) will be administered intravenously (IV) every 3 weeks in a 21-day cycle."

Trial Locations (9)

10016

NGM Clinical Study Site, New York

33612

NGM Clinical Study Site, Tampa

34232

NGM Clinical Study Site, Sarasota

49546

NGM Clinical Study Site, Grand Rapids

73104

NGM Clinical Study Site, Oklahoma City

77030

NGM Clinical Study Site, Houston

78758

NGM Clinical Study Site, Austin

85234

NGM Clinical Study Site, Gilbert

90025

NGM Clinical Study Site, Los Angeles